News & Press: Latest News

MDMA Statement on the Enactment of the “SUPPORT for Patients and Communities Act"

Wednesday, October 24, 2018  
Share |

MDMA Statement on the Enactment of the “SUPPORT for Patients and Communities Act”

 

Washington, D.C. – Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), issued the following statement regarding President Trump’s signing of H.R. 6, the “SUPPORT for Patients and Communities Act” into law:

“While the United States continues to grapple with the opioid crisis, the overwhelming bipartisan support for the ‘SUPPORT for Patients and Communities Act’ highlights the desire by policy makers to support novel solutions.  Medical technology innovators continue to develop non-opioid alternatives to alleviate chronic and acute pain, depression and other debilitating conditions, and this legislation contains important provisions that will spur their use in clinical settings, allowing patients to benefit from these innovations.

 

“MDMA and the entire medtech ecosystem remains committed to working with all stakeholders to ensure the appropriate role of medical technology as a part of the solution to help solve the opioid crisis, and the ‘SUPPORT for Patients and Communities Act’ represents a major step towards achieving this important goal.”

###